Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 21, 537-544, May 1, 1961]
© 1961 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yunoki, K.
Right arrow Articles by Griffin, A. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yunoki, K.
Right arrow Articles by Griffin, A. C.

Composition and Properties of a Highly Purified Toxohormone Preparation*

Kazuo Yunoki{dagger} and A. Clark Griffin

( Department of Biochemistry, University of Texas M. D. Anderson Hospital and Tumor Institute, Houston, Texas)

The amino acid and lipide composition of a highly active toxohormone preparation (TH2) from human malignant tissues was investigated. Approximately 80 per cent of the TH2 could be accounted for as polypeptide, with leucine, alanine, glutamic, and aspartic acid being present in the highest concentrations. The remaining 20 per cent consisted largely of phospholipides.

The TH2 fraction was divided into various subfractions both by paper chromatographic procedure as well as careful fractionation by use of Amberlite XE-64 columns. Most of the subfractions had approximately the same liver catalase-depressing potency as the TH2. The N-terminal amino acid of the various subfractions of TH2 was shown to be arginine. The minimum molecular weights calculated from the N-terminal arginine ranged from 4200 to 6400. It would thus appear that there are several closely related proteolipides of relatively low molecular weight, all possessing toxohormone activity.

From this study we believe that toxohormone activity requires the presence of both a polypeptide and a lipide (probably a phospholipide) component. Acid or enzymatic hydrolysis almost completely destroyed the toxohormone activity, indicating that the peptide is essential. Conclusive evidence as to the absolute necessity of a lipide component for toxohormone activity has not been obtained.

* Supported by research grants from the Robert A. Welch Foundation and the American Cancer Society, P-26A and 209-A. We are indebted to Dr. B. G. Creech, Methodist Hospital, for carrying out the lipide analysis, and to Dr. J. M. Prescott and Mr. W. T. Williams, Department of Biochemistry, Agricultural and Mechanical College of Texas, for the amino acid analysis on the TH2 preparation.

{dagger} On leave from Department of Internal Medicine, Kagoshima University School of Medicine, Kagoshima, Japan.

Received 10/20/60.


This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
H. Rubin
Cancer cachexia: Its correlations and causes
PNAS, April 29, 2003; 100(9): 5384 - 5389.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1961 by the American Association for Cancer Research.